Phillip M. Arlen, M.D.
CEO, Neogenix Oncology

Philip M. Arlen, MD is the Chief Executive Officer of Neogenix Oncology. He joined Neogenix as President and Chief Medical Officer of the Company in July 2008. Prior to 2008, Dr. Arlen spent 11 years at the National Cancer Institute, USA, most recently as the Director of the Clinical Research Group for the Laboratory of Tumor Immunology and Oncology. At the NCI, Dr. Arlen focused on the development of a programmatic approach to vaccine clinical trials conducted at the NCI as well as at numerous other Cancer Centers throughout the US. Dr. Arlen was the Principal Investigator and/or Associate Investigator on numerous clinical trials involving the use of cancer vaccines and other immunostimulatory molecules.